{"transactions":[{"id":723672,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2026-06-29T20:30:20.000Z","date":"2026-06-25","kind":"purchase","planned":false,"acquired":true,"shares":50055,"price":4.1175,"value":206101.4625,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $4.30 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":673759,"source":{"system":"sec-edgar","filing":"0000902664-26-002945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266426002945/ownership.xml","form_type":"4"}},{"id":767331,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45093,"kind":"person","name":"Sondhi Dolan","position":1,"cik":"0001986720","reported_name":"Sondhi Dolan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-21T20:14:14.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":10539,"derivative":{"exercise_price":5.08,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001986720-26-000002","document":"form4-05212026_080510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000198672026000002/form4-05212026_080510.xml","form_type":"4"}},{"id":768047,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":37267,"kind":"person","name":"Porter Derrell","position":1,"cik":"0001706400","reported_name":"Porter Derrell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-21T20:13:40.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":10539,"derivative":{"exercise_price":5.08,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001706400-26-000002","document":"form4-05212026_080536.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706400/000170640026000002/form4-05212026_080536.xml","form_type":"4"}},{"id":767741,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45188,"kind":"person","name":"Kassberg Thomas Richard","position":1,"cik":"0001303811","reported_name":"Kassberg Thomas Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-21T20:13:02.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":10539,"derivative":{"exercise_price":5.08,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001303811-26-000002","document":"form4-05212026_080558.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303811/000130381126000002/form4-05212026_080558.xml","form_type":"4"}},{"id":767404,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45109,"kind":"person","name":"Kapadia Sandip","position":1,"cik":"0001677141","reported_name":"Kapadia Sandip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-21T20:12:16.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":10539,"derivative":{"exercise_price":5.08,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001677141-26-000006","document":"form4-05212026_080513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677141/000167714126000006/form4-05212026_080513.xml","form_type":"4"}},{"id":767704,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":40436,"kind":"person","name":"GOWEN MAXINE","position":1,"cik":"0001280044","reported_name":"GOWEN MAXINE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-21T20:11:27.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":10539,"derivative":{"exercise_price":5.08,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001280044-26-000002","document":"form4-05212026_080523.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280044/000128004426000002/form4-05212026_080523.xml","form_type":"4"}},{"id":767495,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-21T20:10:38.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":10539,"derivative":{"exercise_price":5.08,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001571469-26-000002","document":"form4-05212026_080534.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000157146926000002/form4-05212026_080534.xml","form_type":"4"}},{"id":834403,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-18T20:07:20.000Z","date":"2026-03-16","kind":"grant","planned":false,"acquired":true,"shares":15610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 16, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":15610,"derivative":{"exercise_price":7.64,"expiration_date":"2035-03-16","underlying":"Common Stock","underlying_shares":15610},"source":{"system":"sec-edgar","filing":"0001987062-26-000002","document":"form4-03182026_080313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000198706226000002/form4-03182026_080313.xml","form_type":"4"}},{"id":835298,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":58906,"kind":"person","name":"Chou William","position":1,"cik":"0001949693","reported_name":"Chou William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-18T20:06:33.000Z","date":"2026-03-16","kind":"grant","planned":false,"acquired":true,"shares":58000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 16, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":58000,"derivative":{"exercise_price":7.64,"expiration_date":"2035-03-16","underlying":"Common Stock","underlying_shares":58000},"source":{"system":"sec-edgar","filing":"0001949693-26-000002","document":"form4-03182026_080328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1949693/000194969326000002/form4-03182026_080328.xml","form_type":"4"}},{"id":941167,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":58906,"kind":"person","name":"Chou William","position":1,"cik":"0001949693","reported_name":"Chou William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-12T21:03:52.000Z","date":"2026-01-08","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001949693-26-000001","document":"form4-01122026_090148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1949693/000194969326000001/form4-01122026_090148.xml","form_type":"4"}},{"id":941166,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":58906,"kind":"person","name":"Chou William","position":1,"cik":"0001949693","reported_name":"Chou William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-01-12T21:03:52.000Z","date":"2026-01-08","kind":"sale","planned":false,"acquired":false,"shares":4076,"price":18.4394,"value":75158.9944,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $18.13 to $19.3061 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 with regard to the block trade."}],"balance_after":6524,"source":{"system":"sec-edgar","filing":"0001949693-26-000001","document":"form4-01122026_090148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1949693/000194969326000001/form4-01122026_090148.xml","form_type":"4"}},{"id":941165,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":58906,"kind":"person","name":"Chou William","position":1,"cik":"0001949693","reported_name":"Chou William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-01-12T21:03:52.000Z","date":"2026-01-08","kind":"exercise","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 200 shares acquired on May 16, 2024, 200 shares acquired on May 15, 2025 and 200 shares acquired on November 15, 2025 under the 2020 Employee Stock Purchase Plan."}],"balance_after":10600,"source":{"system":"sec-edgar","filing":"0001949693-26-000001","document":"form4-01122026_090148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1949693/000194969326000001/form4-01122026_090148.xml","form_type":"4"}},{"id":940682,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-12T21:03:14.000Z","date":"2026-01-08","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001987062-26-000001","document":"form4-01122026_090110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000198706226000001/form4-01122026_090110.xml","form_type":"4"}},{"id":940681,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2026-01-12T21:03:14.000Z","date":"2026-01-08","kind":"sale","planned":false,"acquired":false,"shares":2062,"price":18.4394,"value":38022.0428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $18.13 to $19.3061 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 with regard to the block trade."}],"balance_after":5402,"source":{"system":"sec-edgar","filing":"0001987062-26-000001","document":"form4-01122026_090110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000198706226000001/form4-01122026_090110.xml","form_type":"4"}},{"id":940680,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2026-01-12T21:03:14.000Z","date":"2026-01-08","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 200 shares acquired on May 15, 2025 and 200 shares acquired on November 15, 2025 under the 2020 Employee Stock Purchase Plan."}],"balance_after":7464,"source":{"system":"sec-edgar","filing":"0001987062-26-000001","document":"form4-01122026_090110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000198706226000001/form4-01122026_090110.xml","form_type":"4"}},{"id":957838,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-12-29T21:15:26.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001987062-25-000002","document":"form4-12292025_091215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000198706225000002/form4-12292025_091215.xml","form_type":"4"}},{"id":958355,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":58906,"kind":"person","name":"Chou William","position":1,"cik":"0001949693","reported_name":"Chou William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-12-29T21:14:33.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001949693-25-000002","document":"form4-12292025_091229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1949693/000194969325000002/form4-12292025_091229.xml","form_type":"4"}},{"id":1040112,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:05:45.000Z","date":"2025-09-15","kind":"purchase","planned":false,"acquired":true,"shares":11900,"price":6.9895,"value":83175.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.94 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":623704,"source":{"system":"sec-edgar","filing":"0000902664-25-004079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004079/ownership.xml","form_type":"4"}},{"id":1040111,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:05:45.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":19783,"price":6.9908,"value":138298.9964,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":611804,"source":{"system":"sec-edgar","filing":"0000902664-25-004079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004079/ownership.xml","form_type":"4"}},{"id":1040110,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (Common Stock)","published_at":"2025-09-16T00:05:45.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":325,"price":6.9558,"value":2260.635,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.915 to $6.985 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":592021,"source":{"system":"sec-edgar","filing":"0000902664-25-004079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004079/ownership.xml","form_type":"4"}},{"id":1081837,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-24T22:12:54.000Z","date":"2025-07-24","kind":"purchase","planned":false,"acquired":true,"shares":66423,"price":5.7127,"value":379454.6721,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.535 to $5.9 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":591696,"source":{"system":"sec-edgar","filing":"0000902664-25-003152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425003152/ownership.xml","form_type":"4"}},{"id":1081836,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-24T22:12:54.000Z","date":"2025-07-23","kind":"purchase","planned":false,"acquired":true,"shares":49302,"price":5.7408,"value":283032.9216,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.675 to $5.8 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":525273,"source":{"system":"sec-edgar","filing":"0000902664-25-003152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425003152/ownership.xml","form_type":"4"}},{"id":1081835,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-07-24T22:12:54.000Z","date":"2025-07-22","kind":"purchase","planned":false,"acquired":true,"shares":13123,"price":5.4361,"value":71337.9403,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.33 to $5.475 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Persons' holdings have been adjusted to reflect the 1-for-20 reverse stock split of the Issuer effective on July 14, 2025, as disclosed on the Current Report on Form 8-K filed by the Issuer with the SEC on July 14, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":475971,"source":{"system":"sec-edgar","filing":"0000902664-25-003152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425003152/ownership.xml","form_type":"4"}},{"id":1101256,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T21:10:11.000Z","date":"2025-06-26","kind":"sale","planned":false,"acquired":false,"shares":213257,"price":0.33,"value":70374.81,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6066343,"source":{"system":"sec-edgar","filing":"0000947871-25-000629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000629/ownership.xml","form_type":"4"}},{"id":1101255,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T21:10:11.000Z","date":"2025-06-25","kind":"sale","planned":false,"acquired":false,"shares":138800,"price":0.33,"value":45804.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6279600,"source":{"system":"sec-edgar","filing":"0000947871-25-000629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000629/ownership.xml","form_type":"4"}},{"id":1101254,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T21:10:11.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":231600,"price":0.35,"value":81060.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6418400,"source":{"system":"sec-edgar","filing":"0000947871-25-000629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000629/ownership.xml","form_type":"4"}},{"id":1128875,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45109,"kind":"person","name":"Kapadia Sandip","position":1,"cik":"0001677141","reported_name":"Kapadia Sandip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-31T01:41:02.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015077","document":"form4-05312025_010556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677141/000141588925015077/form4-05312025_010556.xml","form_type":"4"}},{"id":1129091,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":40436,"kind":"person","name":"GOWEN MAXINE","position":1,"cik":"0001280044","reported_name":"GOWEN MAXINE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:31:13.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015059","document":"form4-05302025_110508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280044/000141588925015059/form4-05302025_110508.xml","form_type":"4"}},{"id":1128915,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:30:26.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015058","document":"form4-05302025_110515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000141588925015058/form4-05302025_110515.xml","form_type":"4"}},{"id":1129290,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":37267,"kind":"person","name":"Porter Derrell","position":1,"cik":"0001706400","reported_name":"Porter Derrell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:29:26.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015057","document":"form4-05302025_110521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706400/000141588925015057/form4-05302025_110521.xml","form_type":"4"}},{"id":1128910,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:28:38.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015056","document":"form4-05302025_110532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000141588925015056/form4-05302025_110532.xml","form_type":"4"}},{"id":1128824,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45093,"kind":"person","name":"Sondhi Dolan","position":1,"cik":"0001986720","reported_name":"Sondhi Dolan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:27:46.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015055","document":"form4-05302025_110538.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588925015055/form4-05302025_110538.xml","form_type":"4"}},{"id":1129111,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45188,"kind":"person","name":"Kassberg Thomas Richard","position":1,"cik":"0001303811","reported_name":"Kassberg Thomas Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:26:39.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":143789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":143789,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":143789},"source":{"system":"sec-edgar","filing":"0001415889-25-015054","document":"form4-05302025_110528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303811/000141588925015054/form4-05302025_110528.xml","form_type":"4"}},{"id":1166632,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-24T21:38:49.000Z","date":"2025-04-24","kind":"sale","planned":false,"acquired":false,"shares":68195,"price":0.32,"value":21822.4,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6650000,"source":{"system":"sec-edgar","filing":"0000947871-25-000423","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000423/ownership.xml","form_type":"4"}},{"id":1166631,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-24T21:38:49.000Z","date":"2025-04-23","kind":"sale","planned":false,"acquired":false,"shares":89328,"price":0.34,"value":30371.52,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6718195,"source":{"system":"sec-edgar","filing":"0000947871-25-000423","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000423/ownership.xml","form_type":"4"}},{"id":1166630,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-24T21:38:49.000Z","date":"2025-04-22","kind":"sale","planned":false,"acquired":false,"shares":78049,"price":0.34,"value":26536.66,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6807523,"source":{"system":"sec-edgar","filing":"0000947871-25-000423","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000423/ownership.xml","form_type":"4"}},{"id":1170137,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T22:10:47.000Z","date":"2025-04-17","kind":"sale","planned":false,"acquired":false,"shares":77090,"price":0.33,"value":25439.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6885572,"source":{"system":"sec-edgar","filing":"0000947871-25-000415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000415/ownership.xml","form_type":"4"}},{"id":1170136,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T22:10:47.000Z","date":"2025-04-16","kind":"sale","planned":false,"acquired":false,"shares":61638,"price":0.33,"value":20340.54,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6962662,"source":{"system":"sec-edgar","filing":"0000947871-25-000415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000415/ownership.xml","form_type":"4"}},{"id":1170135,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T22:10:47.000Z","date":"2025-04-15","kind":"sale","planned":false,"acquired":false,"shares":10326,"price":0.38,"value":3923.88,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7024300,"source":{"system":"sec-edgar","filing":"0000947871-25-000415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000415/ownership.xml","form_type":"4"}},{"id":1198214,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T21:12:20.000Z","date":"2025-03-15","kind":"grant","planned":false,"acquired":true,"shares":278386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":278386,"derivative":{"exercise_price":0.387,"expiration_date":"2035-03-15","underlying":"Common Stock","underlying_shares":278386},"source":{"system":"sec-edgar","filing":"0001415889-25-008443","document":"form4-03182025_090317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588925008443/form4-03182025_090317.xml","form_type":"4"}},{"id":1200503,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":58906,"kind":"person","name":"Chou William","position":1,"cik":"0001949693","reported_name":"Chou William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T21:11:39.000Z","date":"2025-03-15","kind":"grant","planned":false,"acquired":true,"shares":779533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":779533,"derivative":{"exercise_price":0.387,"expiration_date":"2035-03-15","underlying":"Common Stock","underlying_shares":779533},"source":{"system":"sec-edgar","filing":"0001415889-25-008442","document":"form4-03182025_090335.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1949693/000141588925008442/form4-03182025_090335.xml","form_type":"4"}},{"id":1198213,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":81793,"kind":"person","name":"Cale Edgar B.","position":1,"cik":"0001799783","reported_name":"Cale Edgar B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & CORPORATE SECRETARY"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T21:11:05.000Z","date":"2025-03-15","kind":"grant","planned":false,"acquired":true,"shares":278386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":278386,"derivative":{"exercise_price":0.387,"expiration_date":"2035-03-15","underlying":"Common Stock","underlying_shares":278386},"source":{"system":"sec-edgar","filing":"0001415889-25-008441","document":"form4-03182025_090302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588925008441/form4-03182025_090302.xml","form_type":"4"}},{"id":1271027,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T21:21:37.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the RSUs vested on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"1/3 of the RSUs vested on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001415889-25-003728","document":"form4-02122025_090233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588925003728/form4-02122025_090233.xml","form_type":"4"}},{"id":1271026,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-02-12T21:21:37.000Z","date":"2025-02-11","kind":"sale","planned":false,"acquired":false,"shares":3183,"price":0.5296,"value":1685.7168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $0.51 to $0.58 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 with regard to the block trade."}],"balance_after":41283,"source":{"system":"sec-edgar","filing":"0001415889-25-003728","document":"form4-02122025_090233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588925003728/form4-02122025_090233.xml","form_type":"4"}},{"id":1271025,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-02-12T21:21:37.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":true,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired on May 16, 2024 and 4,000 shares acquired on November 16, 2024 under the 2020 Employee Stock Purchase Plan."}],"balance_after":44466,"source":{"system":"sec-edgar","filing":"0001415889-25-003728","document":"form4-02122025_090233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588925003728/form4-02122025_090233.xml","form_type":"4"}},{"id":1303819,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T22:17:16.000Z","date":"2025-01-14","kind":"sale","planned":false,"acquired":false,"shares":79024,"price":0.6,"value":47414.4,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.58 to a high of $0.63 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7034626,"source":{"system":"sec-edgar","filing":"0000947871-25-000034","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000034/ownership.xml","form_type":"4"}},{"id":1303818,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T22:17:16.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":17986,"price":0.64,"value":11511.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.63 to a high of $0.66 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7113650,"source":{"system":"sec-edgar","filing":"0000947871-25-000034","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000034/ownership.xml","form_type":"4"}},{"id":1303817,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T22:17:16.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":126209,"price":0.66,"value":83297.94,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.61 to a high of $0.70 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7131636,"source":{"system":"sec-edgar","filing":"0000947871-25-000034","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000034/ownership.xml","form_type":"4"}},{"id":1307070,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-08T23:09:47.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":75007,"price":0.68,"value":51004.76,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.65 to a high of $0.74 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7257845,"source":{"system":"sec-edgar","filing":"0000947871-25-000021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000021/ownership.xml","form_type":"4"}},{"id":1307069,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-08T23:09:47.000Z","date":"2025-01-07","kind":"sale","planned":false,"acquired":false,"shares":52536,"price":0.71,"value":37300.56,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.70 to a high of $0.77 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7332852,"source":{"system":"sec-edgar","filing":"0000947871-25-000021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000021/ownership.xml","form_type":"4"}},{"id":1307068,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-08T23:09:47.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":19481,"price":0.77,"value":15000.37,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.76 to a high of $0.79 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7385388,"source":{"system":"sec-edgar","filing":"0000947871-25-000021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000021/ownership.xml","form_type":"4"}},{"id":1319626,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share","published_at":"2024-12-31T21:05:36.000Z","date":"2024-12-27","kind":"purchase","planned":false,"acquired":true,"shares":373645,"price":0.6451,"value":241038.3895,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6426 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":9256953,"source":{"system":"sec-edgar","filing":"0000902664-24-007075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424007075/ownership.xml","form_type":"4"}},{"id":1322140,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-26T21:34:10.000Z","date":"2024-12-20","kind":"sale","planned":false,"acquired":false,"shares":230321,"price":0.6,"value":138192.6,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7404869,"source":{"system":"sec-edgar","filing":"0000947871-24-001037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124001037/ownership.xml","form_type":"4"}},{"id":1336279,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T22:32:47.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":80,"price":0.8,"value":64.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7635190,"source":{"system":"sec-edgar","filing":"0000947871-24-000998","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000998/ownership.xml","form_type":"4"}},{"id":1336278,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T22:32:47.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":8015,"price":0.8,"value":6412.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.80 to a high of $0.8094 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7635270,"source":{"system":"sec-edgar","filing":"0000947871-24-000998","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000998/ownership.xml","form_type":"4"}},{"id":1336277,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T22:32:47.000Z","date":"2024-12-09","kind":"sale","planned":false,"acquired":false,"shares":54181,"price":0.84,"value":45512.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.80 to a high of $0.87 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7643285,"source":{"system":"sec-edgar","filing":"0000947871-24-000998","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000998/ownership.xml","form_type":"4"}},{"id":1340797,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-07T00:07:53.000Z","date":"2024-12-06","kind":"sale","planned":false,"acquired":false,"shares":20903,"price":0.82,"value":17140.46,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.81 to a high of $0.83 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7697466,"source":{"system":"sec-edgar","filing":"0000947871-24-000995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000995/ownership.xml","form_type":"4"}},{"id":1340796,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-07T00:07:53.000Z","date":"2024-12-04","kind":"sale","planned":false,"acquired":false,"shares":76200,"price":0.79,"value":60198.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.75 to a high of $0.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7718369,"source":{"system":"sec-edgar","filing":"0000947871-24-000995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000995/ownership.xml","form_type":"4"}},{"id":1348808,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T23:11:20.000Z","date":"2024-11-27","kind":"purchase","planned":false,"acquired":true,"shares":29300,"price":0.6711,"value":19663.23,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.661 to $0.6838 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8883308,"source":{"system":"sec-edgar","filing":"0000902664-24-006799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424006799/ownership.xml","form_type":"4"}},{"id":1348807,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T23:11:20.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":167055,"price":0.7075,"value":118191.4125,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.65 to $0.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8854008,"source":{"system":"sec-edgar","filing":"0000902664-24-006799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424006799/ownership.xml","form_type":"4"}},{"id":1348806,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2024-11-27T23:11:20.000Z","date":"2024-11-25","kind":"purchase","planned":false,"acquired":true,"shares":259998,"price":0.5641,"value":146664.8718,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.49 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8686953,"source":{"system":"sec-edgar","filing":"0000902664-24-006799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424006799/ownership.xml","form_type":"4"}},{"id":1393608,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":81793,"kind":"person","name":"Cale Edgar B.","position":1,"cik":"0001799783","reported_name":"Cale Edgar B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & CORPORATE SECRETARY"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-02T20:41:45.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on September 1, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.7,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-024433","document":"form4-10022024_081040.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588924024433/form4-10022024_081040.xml","form_type":"4"}},{"id":1394096,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45188,"kind":"person","name":"Kassberg Thomas Richard","position":1,"cik":"0001303811","reported_name":"Kassberg Thomas Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-02T20:35:20.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":174139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning on October 10, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":174139,"derivative":{"exercise_price":0.7,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":174139},"source":{"system":"sec-edgar","filing":"0001415889-24-024416","document":"form4-10022024_081016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303811/000141588924024416/form4-10022024_081016.xml","form_type":"4"}},{"id":1401124,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:51:33.000Z","date":"2024-09-19","kind":"sale","planned":false,"acquired":false,"shares":39300,"price":0.71,"value":27903.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.70 to a high of $0.73 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7794569,"source":{"system":"sec-edgar","filing":"0000947871-24-000769","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000769/ownership.xml","form_type":"4"}},{"id":1404010,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T22:38:14.000Z","date":"2024-09-18","kind":"sale","planned":false,"acquired":false,"shares":25631,"price":0.73,"value":18710.63,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7833869,"source":{"system":"sec-edgar","filing":"0000947871-24-000763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000763/ownership.xml","form_type":"4"}},{"id":1404009,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T22:38:14.000Z","date":"2024-09-17","kind":"sale","planned":false,"acquired":false,"shares":111400,"price":0.73,"value":81322.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.73 to a high of $0.75 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7859500,"source":{"system":"sec-edgar","filing":"0000947871-24-000763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000763/ownership.xml","form_type":"4"}},{"id":1404008,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T22:38:14.000Z","date":"2024-09-16","kind":"sale","planned":false,"acquired":false,"shares":63100,"price":0.74,"value":46694.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.73 to a high of $0.78 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7970900,"source":{"system":"sec-edgar","filing":"0000947871-24-000763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000763/ownership.xml","form_type":"4"}},{"id":1503268,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T21:43:57.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":47693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":47693,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":47693},"source":{"system":"sec-edgar","filing":"0001415889-24-014333","document":"form4-05232024_090550.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000141588924014333/form4-05232024_090550.xml","form_type":"4"}},{"id":1503475,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":40436,"kind":"person","name":"GOWEN MAXINE","position":1,"cik":"0001280044","reported_name":"GOWEN MAXINE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T20:56:03.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":47693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":47693,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":47693},"source":{"system":"sec-edgar","filing":"0001415889-24-014313","document":"form4-05232024_080547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280044/000141588924014313/form4-05232024_080547.xml","form_type":"4"}},{"id":1503208,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45109,"kind":"person","name":"Kapadia Sandip","position":1,"cik":"0001677141","reported_name":"Kapadia Sandip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T20:55:06.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":47693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":47693,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":47693},"source":{"system":"sec-edgar","filing":"0001415889-24-014312","document":"form4-05232024_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677141/000141588924014312/form4-05232024_080500.xml","form_type":"4"}},{"id":1503265,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T20:53:37.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":47693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":47693,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":47693},"source":{"system":"sec-edgar","filing":"0001415889-24-014311","document":"form4-05232024_080531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000141588924014311/form4-05232024_080531.xml","form_type":"4"}},{"id":1503137,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45093,"kind":"person","name":"Sondhi Dolan","position":1,"cik":"0001986720","reported_name":"Sondhi Dolan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T20:52:31.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":39092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":39092,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":39092},"source":{"system":"sec-edgar","filing":"0001415889-24-014310","document":"form4-05232024_080524.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588924014310/form4-05232024_080524.xml","form_type":"4"}},{"id":1503735,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":37267,"kind":"person","name":"Porter Derrell","position":1,"cik":"0001706400","reported_name":"Porter Derrell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T20:51:39.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":47693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":47693,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":47693},"source":{"system":"sec-edgar","filing":"0001415889-24-014309","document":"form4-05232024_080531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706400/000141588924014309/form4-05232024_080531.xml","form_type":"4"}},{"id":1566988,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:11:04.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":227000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":227000,"derivative":{"exercise_price":1.5,"underlying":"Common Stock","underlying_shares":227000},"source":{"system":"sec-edgar","filing":"0001415889-24-008495","document":"form4-03192024_080352.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588924008495/form4-03192024_080352.xml","form_type":"4"}},{"id":1569602,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":58906,"kind":"person","name":"Chou William","position":1,"cik":"0001949693","reported_name":"Chou William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:09:07.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":575000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":575000,"derivative":{"exercise_price":1.5,"underlying":"Common Stock","underlying_shares":575000},"source":{"system":"sec-edgar","filing":"0001415889-24-008489","document":"form4-03192024_080351.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1949693/000141588924008489/form4-03192024_080351.xml","form_type":"4"}},{"id":1566987,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":81793,"kind":"person","name":"Cale Edgar B.","position":1,"cik":"0001799783","reported_name":"Cale Edgar B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & CORPORATE SECRETARY"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:08:16.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":203000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":203000,"derivative":{"exercise_price":1.5,"underlying":"Common Stock","underlying_shares":203000},"source":{"system":"sec-edgar","filing":"0001415889-24-008487","document":"form4-03192024_080350.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588924008487/form4-03192024_080350.xml","form_type":"4"}},{"id":1569569,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T16:09:54.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":203000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":203000,"derivative":{"exercise_price":1.5,"underlying":"Common Stock","underlying_shares":203000},"source":{"system":"sec-edgar","filing":"0001415889-24-008491","document":"form4-03192024_080347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000141588924008491/form4-03192024_080347.xml","form_type":"4"}},{"id":1645241,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, INTERIM CFO"}}],"security":"Restricted Stock Unit","published_at":"2024-02-14T00:36:54.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":8000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001415889-24-003640","document":"form4-02142024_120246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588924003640/form4-02142024_120246.xml","form_type":"4"}},{"id":1645240,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, INTERIM CFO"}}],"security":"Common Stock","published_at":"2024-02-14T00:36:54.000Z","date":"2024-02-13","kind":"sale","planned":false,"acquired":false,"shares":1470,"price":0.97,"value":1425.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."}],"balance_after":28466,"source":{"system":"sec-edgar","filing":"0001415889-24-003640","document":"form4-02142024_120246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588924003640/form4-02142024_120246.xml","form_type":"4"}},{"id":1645239,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, INTERIM CFO"}}],"security":"Common Stock","published_at":"2024-02-14T00:36:54.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":true,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":29936,"source":{"system":"sec-edgar","filing":"0001415889-24-003640","document":"form4-02142024_120246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000141588924003640/form4-02142024_120246.xml","form_type":"4"}},{"id":1646616,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-13T19:34:59.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-003637","document":"form4-02142024_120249.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000141588924003637/form4-02142024_120249.xml","form_type":"4"}},{"id":1646615,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-13T19:34:59.000Z","date":"2022-02-10","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-003637","document":"form4-02142024_120249.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000141588924003637/form4-02142024_120249.xml","form_type":"4"}},{"id":1646614,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-13T19:34:59.000Z","date":"2022-02-10","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as of 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":4.52,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-003637","document":"form4-02142024_120249.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000141588924003637/form4-02142024_120249.xml","form_type":"4"}},{"id":1646613,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-13T19:34:59.000Z","date":"2021-08-16","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the total shares on August 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":130000,"derivative":{"exercise_price":10.84,"expiration_date":"2031-08-15","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-24-003637","document":"form4-02142024_120249.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000141588924003637/form4-02142024_120249.xml","form_type":"4"}},{"id":1646612,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-13T19:34:59.000Z","date":"2024-02-13","kind":"sale","planned":false,"acquired":false,"shares":1638,"price":0.97,"value":1588.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."}],"balance_after":48631,"source":{"system":"sec-edgar","filing":"0001415889-24-003637","document":"form4-02142024_120249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000141588924003637/form4-02142024_120249.xml","form_type":"4"}},{"id":1646611,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-13T19:34:59.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":50269,"source":{"system":"sec-edgar","filing":"0001415889-24-003637","document":"form4-02142024_120249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000141588924003637/form4-02142024_120249.xml","form_type":"4"}},{"id":1690555,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Interim CFO"}}],"security":"Restricted Stock Unit","published_at":"2024-01-03T21:20:30.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-000367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919124000367/doc4.xml","form_type":"4"}},{"id":1690554,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Interim CFO"}}],"security":"Common Stock","published_at":"2024-01-03T21:20:30.000Z","date":"2024-01-02","kind":"sale","planned":false,"acquired":false,"shares":10672,"price":0.91,"value":9711.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."}],"balance_after":25936,"source":{"system":"sec-edgar","filing":"0001209191-24-000367","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919124000367/doc4.xml","form_type":"4"}},{"id":1690553,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Interim CFO"}}],"security":"Common Stock","published_at":"2024-01-03T21:20:30.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,082 shares acquired on May 13, 2022 and 3,526 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan."}],"balance_after":36608,"source":{"system":"sec-edgar","filing":"0001209191-24-000367","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919124000367/doc4.xml","form_type":"4"}},{"id":1690552,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":81793,"kind":"person","name":"Cale Edgar B.","position":1,"cik":"0001799783","reported_name":"Cale Edgar B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & Corporate Secretary"}}],"security":"Restricted Stock Unit","published_at":"2024-01-03T21:19:50.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-24-000365","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919124000365/doc4.xml","form_type":"4"}},{"id":1690551,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":81793,"kind":"person","name":"Cale Edgar B.","position":1,"cik":"0001799783","reported_name":"Cale Edgar B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & Corporate Secretary"}}],"security":"Common Stock","published_at":"2024-01-03T21:19:50.000Z","date":"2024-01-02","kind":"sale","planned":false,"acquired":false,"shares":15813,"price":0.91,"value":14389.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."}],"balance_after":45995,"source":{"system":"sec-edgar","filing":"0001209191-24-000365","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919124000365/doc4.xml","form_type":"4"}},{"id":1690550,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":81793,"kind":"person","name":"Cale Edgar B.","position":1,"cik":"0001799783","reported_name":"Cale Edgar B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & Corporate Secretary"}}],"security":"Common Stock","published_at":"2024-01-03T21:19:50.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,024 shares acquired on May 14, 2021, 531 shares acquired on November 15, 2021, 3,082 shares acquired on May 13, 2022, and 3,967 shares acquired under the 2020 Employee Stock Purchase Plan."}],"balance_after":61808,"source":{"system":"sec-edgar","filing":"0001209191-24-000365","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919124000365/doc4.xml","form_type":"4"}},{"id":1693358,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-03T16:21:31.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-24-000369","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000120919124000369/doc4.xml","form_type":"4"}},{"id":1693357,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-03T16:21:31.000Z","date":"2024-01-02","kind":"sale","planned":false,"acquired":false,"shares":15813,"price":0.91,"value":14389.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."}],"balance_after":45269,"source":{"system":"sec-edgar","filing":"0001209191-24-000369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000120919124000369/doc4.xml","form_type":"4"}},{"id":1693356,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":62855,"kind":"person","name":"Forman Mark S","position":1,"cik":"0001922353","reported_name":"Forman Mark S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-03T16:21:31.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan."}],"balance_after":61082,"source":{"system":"sec-edgar","filing":"0001209191-24-000369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922353/000120919124000369/doc4.xml","form_type":"4"}},{"id":1819399,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":110997,"kind":"person","name":"King Simona","position":1,"cik":"0001879312","reported_name":"King Simona","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-01T16:36:49.000Z","date":"2023-07-28","kind":"exercise","planned":false,"acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001209191-23-043998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1879312/000120919123043998/doc4.xml","form_type":"4"}},{"id":1819398,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":110997,"kind":"person","name":"King Simona","position":1,"cik":"0001879312","reported_name":"King Simona","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-01T16:36:49.000Z","date":"2023-07-28","kind":"sale","planned":false,"acquired":false,"shares":11453,"price":0.88,"value":10078.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a \"sell to cover\" transaction."}],"balance_after":23994,"source":{"system":"sec-edgar","filing":"0001209191-23-043998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1879312/000120919123043998/doc4.xml","form_type":"4"}},{"id":1819397,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":110997,"kind":"person","name":"King Simona","position":1,"cik":"0001879312","reported_name":"King Simona","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-01T16:36:49.000Z","date":"2023-07-28","kind":"exercise","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":35447,"source":{"system":"sec-edgar","filing":"0001209191-23-043998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879312/000120919123043998/doc4.xml","form_type":"4"}},{"id":1820206,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":45093,"kind":"person","name":"Sondhi Dolan","position":1,"cik":"0001986720","reported_name":"Sondhi Dolan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-07-31T21:34:07.000Z","date":"2023-07-27","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares on August 28, 2023, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.848,"expiration_date":"2033-07-27","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001209191-23-043872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919123043872/doc4.xml","form_type":"4"}},{"id":1821291,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":57813,"kind":"person","name":"Borthwick Kathleen","position":1,"cik":"0001987062","reported_name":"Borthwick Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Interim CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-07-28T22:34:32.000Z","date":"2023-07-28","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the total shares on July 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":0.8773,"expiration_date":"2033-07-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-043725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787297/000120919123043725/doc4.xml","form_type":"4"}}],"next_cursor":"2023-07-28T22:34:32.000000Z,1821291"}